Novonesis

Novonesis is an operating company whose capital allocation is directed by the executive leadership team under CEO Ester Baiget, rather than through a separate investment office. The firm is majority-owned by Novo Holdings A/S, the investment arm of the Novo Nordisk Foundation, which provides governance oversight. Investment decisions are embedded in the company's operational strategy, which prioritizes in-house innovation and manufacturing expansion over third-party fund commitments.

Novonesis sources intellectual property primarily through internal R&D conducted at its Danish innovation campuses and satellite centers in India and the United States. Its innovation model relies on studying naturally occurring microbes and enzymes, then engineering them for specific uses in over 30 industries. This approach is supplemented by targeted acquisitions, such as the purchase of dsm-firmenich's animal feed enzyme business in 2025.

Novonesis operates through direct corporate transaction structures, including internal R&D allocations and specific acquisitions. The firm does not maintain a traditional corporate venture capital fund or invest as a limited partner in external venture or growth funds. Its business partnerships, including the long-running Feed Enzyme Alliance with dsm-firmenich, represent operational joint ventures rather than financial investment vehicles.

Novonesis targets the full value chain in industrial biosolutions, from late-stage research and development through to scaled manufacturing. It focuses on the food and beverage, human health, and planetary health sectors. This translates into enzyme engineering for agricultural yields, probiotic strain development for consumer health, and industrial process optimization for manufacturing partners.

Novonesis is majority-owned by Novo Holdings A/S, the holding and investment company responsible for managing the assets of the Novo Nordisk Foundation. This structure effectively places Novonesis under a self-governing foundation that channels dividends into scientific research and philanthropic grants, creating a stable long-term ownership model distinct from publicly-traded peers or privately-equity-backed companies.

Novonesis does not operate its own corporate foundation. Instead, its philanthropic alignment flows upward through dividend payments to its parent, Novo Holdings, which finances the Novo Nordisk Foundation. The foundation is one of the world's wealthiest charitable entities, supporting scientific, medical and humanitarian research independent of Novonesis' day-to-day commercial targets.

The firm has set public targets to reduce operational emissions by 75% and supply chain emissions by 35%, using a 2018 baseline. For its 2030 strategy period, it also targets a minimum of 40% representation of the underrepresented gender in senior leadership positions. These targets appear alongside financial objectives and are reported through the company's regular investor and sustainability communications.